Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a large increase in short interest in June. As of June 30th, there was short interest totaling 82,827 shares, an increase of 1,724.4% from the June 15th total of 4,540 shares. Approximately 1.8% of the shares of the stock are short sold. Based on an average daily volume of 262,246 shares, the days-to-cover ratio is currently 0.3 days.

Sonoma Pharmaceuticals Stock Performance

Shares of NASDAQ:SNOA remained flat at $1.26 during midday trading on Friday. The company had a trading volume of 101,758 shares, compared to its average volume of 173,805. The company has a fifty day simple moving average of $1.15 and a two-hundred day simple moving average of $2.22. The company has a market capitalization of $6.03 million, a price-to-earnings ratio of -0.67 and a beta of 1.27. Sonoma Pharmaceuticals has a fifty-two week low of $0.85 and a fifty-two week high of $6.92.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its quarterly earnings data on Tuesday, June 16th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.09). Sonoma Pharmaceuticals had a negative return on equity of 43.95% and a negative net margin of 16.26%.The company had revenue of $5.56 million for the quarter, compared to analyst estimates of $5.57 million.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Sonoma Pharmaceuticals presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

An institutional investor recently raised its stake in Sonoma Pharmaceuticals stock. DRW Securities LLC boosted its position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 257.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 60,977 shares of the company’s stock after purchasing an additional 43,907 shares during the period. DRW Securities LLC owned 3.59% of Sonoma Pharmaceuticals worth $222,000 at the end of the most recent reporting period. 1.95% of the stock is owned by institutional investors.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.